CELL-REPORTS-D-25-07758
Description
Figure 1D: GSDMD-FL, GSDMD-N, tight junction proteins ZO-1 and Occludin in HBMECs infected with or without NMEC at 4 or 8 h p.i., respectively. Figure 3E: GBP5 protein levels in HBMECs that were either uninfected or infected with NMEC WT at 4 h p.i. Figure 3H: GSDMD-FL, cleaved GSDMD-N, Caspase4, and cleaved Caspase4 in HBMECs transfected with GBP5-targeting siRNA. Figure 3M: GSDMD-FL, cleaved GSDMD-N, Caspase4, and cleaved Caspase4 in HBMECs transfected with pcDNA3.1 overexpressing Gbp5. Figure 5H and I: GSDMD-FL and GSDMD-N in HMC3 cells in co-culture system (H) and conditioned supernatants (I). Figure 5J and K: GSDMD-FL and GSDMD-N in HMC3 cells co-cultured with HBMECs following Gbp5 knockdown (J) or overexpression (K). Figure 6D: GSDMD-FL and GSDMD-N in HMC3 cells which were co-cultured for 24 h with HBMECs transfected with indicated siRNA, followed by infection with NMEC WT or ΔmsbB. Figure 6E:GSDMD-FL and GSDMD-N in HMC3 cells which were co-cultured for 24 h with HBMECs transfected with indicated plasmid, followed by infection with NMEC WT or ΔmsbB. Figure 6F: GSDMD-FL and GSDMD-N in HMC3 cells transfected with siRNA targeting Sdc4 were co-cultured for 24 h with HBMECs infected with NMEC WT or ΔmsbB. Figure 6G: GSDMD-FL and GSDMD-N in HMC3 cells transfected with pcDNA3.1 overexpressing Sdc4 were co-cultured for 24 h with HBMECs infected with NMEC WT or ΔmsbB. Figure 6H: GSDMD-FL and GSDMD-N in HMC3 cells which were pretreated with 50 μM salidroside for 2 h, then co-cultured for 24 h with HBMECs. Figure S1E: GSDMD-FL and GSDMD-N in HBMECs infected with NMEC at multiple time points from 0 to 8 h p.i., respectively. Figure S3F: Evaluation of Gbp2, Gbp3, Gbp5 siRNA-mediated knockdown efficiency in HBMECs. Figure S3G: Evaluation of Gbp5 overexpression efficiency in HBMECs. Figure S3M-N: Co-immunoprecipitation analysis of the interaction between GBP5 and Caspase-4 in HBMECs. Figure S4B: GBP5 of primary brain ECs lysates from P18 mice injected intravenously with AAV-X1.1-EGFP and AAV-X1.1-ΔGbp5. Figure S5B: GSDMD-FL and GSDMD-N in co-culture lysates of HBMECs. Figure S5E: GSDMD-FL and cleaved GSDMD-N in supernatants (B) of HBMECs. Figure S5H-K: Western blot analysis of NLRP3, Caspase-4, and cleaved Caspase-4 in HMC3 cells. Figure S6C: ANGPTL4 protein levels in co-culture lysates of HBMECs. Figure S6D: SDC4 protein levels in co-culture lysates of HMC3 cells. Figure S6F-I: Western blot analysis of NLRP3, Caspase-4, and cleaved Caspase-4 in HMC3 cells. Figure S6J: GSDMD-FL in the control or Gsdmd-/- HBMECs. Figure S6L: GSDMD-FL and GSDMD-N in both HBMECs and HMC3 cells in transwell system which HBMECs were pretreated with 20 μM pan-caspase inhibitor Z-VAD-FMK for 30 min, then infected with NMEC WT. Figure S6N: SDC4 of primary MG lysates from P18 mice injected with AAV-MG1.2-EGFP and AAV-MG1.2-ΔSdc4. Figure S6O: GSDMD cleavage and tight junction proteins expression in primary ECs lysates from P18 mice injected with AAV-MG1.2-EGFP and AAV-MG1.2-ΔSdc4.